Using these approaches, we present compelling evidence to suggest activation of FADS1 by icosopent ethyl as well as S1PR2 by fingolimod could be promising therapeutic strategies for MASLD. This evidence concerns the gene FADS1 and metabolic dysfunction-associated steatotic liver disease.